Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
OrthoPediatrics Corp Market Cap
From what 4 stock analysts predict, the share price for OrthoPediatrics Corp (KIDS) might increase by 65.09% in the next year. This is based on a 12-month average estimation for KIDS. Price targets go from $34 to $50. The majority of stock analysts believe KIDS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned KIDS 4 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect OrthoPediatrics Corp to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on KIDS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of KIDS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Turkaly JMP Securities | Market Outperform | $50 | Reiterates | Sep 13, 2024 |
| Richard Newitter Truist Securities | Hold | $34 | Reiterates | Sep 13, 2024 |
| Mike Matson Needham | Buy | $42 | Reiterates | Sep 13, 2024 |
| Mike Matson Needham | Buy | $42 | Reiterates | Aug 16, 2024 |
| Richard Newitter Truist Securities | Hold | $30 | Reiterates | Aug 8, 2024 |
| Samuel Brodovsky Truist Securities | Hold | $35 | Maintains | Jul 16, 2024 |
| Samuel Brodovsky Truist Securities | Hold | $38 | Maintains | May 8, 2024 |
| Mike Matson Needham | Buy | $42 | Maintains | May 7, 2024 |
| David Turkaly JMP Securities | Market Outperform | $50 | Reiterates | May 7, 2024 |
| Mike Matson Needham | Buy | $37 | Reiterates | Apr 10, 2024 |
Piper Sandler | Overweight | Reiterates | Mar 27, 2024 | |
| Samuel Brodovsky Truist Securities | Hold | $32 | Maintains | Mar 8, 2024 |
| Rick Wise Stifel | Buy | $34 | Maintains | Mar 7, 2024 |
| David Turkaly JMP Securities | Market Outperform | $50 | Reiterates | Mar 7, 2024 |
| Mike Matson Needham | Buy | $37 | Reiterates | Mar 7, 2024 |
| Kaila Krum Truist Securities | Hold | $31 | Downgrade | Jan 25, 2024 |
| Richard Newitter Truist Securities | Buy | $39 | Maintains | Dec 22, 2023 |
| David Turkaly JMP Securities | Market Outperform | $50 | Maintains | Dec 7, 2023 |
| Richard Newitter Truist Securities | Buy | $35 | Maintains | Nov 8, 2023 |
| Mike Matson Needham | Buy | $37 | Maintains | Nov 7, 2023 |
When did it IPO
2017
Staff Count
247
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. David R. Bailey
Market Cap
$626.5M
In 2023, KIDS generated $148.7M in revenue, which was a increase of 21.62% from the previous year. This can be seen as a signal that KIDS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - OrthoPediatrics (KIDS) shows signs of support with a hammer chart pattern, and Wall Street analysts are raising earnings estimates, suggesting potential for a near-term turnaround.
Why It Matters - The hammer chart pattern signals a potential reversal in OrthoPediatrics' stock, while upgraded earnings estimates from analysts suggest improved future performance, attracting investor interest.
Mon, 16 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - OrthoPediatrics has launched its Enabling Technologies division, aiming for sustainable revenue growth and expansion into new markets and specialties beyond orthopedics.
Why It Matters - The launch of the Enabling Technologies division signals potential revenue diversification and growth for OrthoPediatrics, which could enhance its market position and investor confidence.
Tue, 17 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Wall Street analysts project a 36.3% upside for OrthoPediatrics (KIDS), supported by positive earnings estimate revisions.
Why It Matters - A 36.3% upside in price targets and positive earnings revisions suggest strong potential for OrthoPediatrics (KIDS), signaling possible growth and investment opportunities.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The Company will provide additional details during its Investor Day on September 12, 2024, which may be relevant for investors.
Why It Matters - The Investor Day may reveal strategic plans, financial forecasts, or new initiatives, impacting stock performance and investor sentiment.
Thu, 29 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - OrthoPediatrics (KIDS) has a consensus price target suggesting a 31.2% upside potential, supported by positive earnings estimate revisions.
Why It Matters - The 31.2% upside potential suggests significant growth for OrthoPediatrics (KIDS), while upward earnings estimate revisions indicate improving financial performance, signaling potential stock appreciation.
Tue, 20 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - OrthoPediatrics Corp. (Nasdaq: KIDS) will host an investor day on September 12, 2024, in New York, focusing on its Specialty Bracing strategy, product pipeline, and financial outlook.
Why It Matters - OrthoPediatrics' upcoming investor day will reveal strategic insights and financial projections, potentially influencing stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
